PINL:VBIVQ - Post Discussion
Post by
whytestocks on Apr 16, 2024 8:00pm
VBI Vaccines Reports Full Year 2023 Financial Results
NEWS: $VBIV VBI Vaccines Reports Full Year 2023 Financial ResultsPreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone Early data from randomize...
VBIV - VBI Vaccines Reports Full Year 2023 Financial Results
Be the first to comment on this post